The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
about
Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndromeThe effects of medications on circulating levels of cardiac natriuretic peptidesComparison of Levosimendan versus Dobutamine in Patients with Moderate to Severe Left Ventricular Dysfunction Undergoing Off-pump Coronary Artery Bypass Grafting: A Randomized Prospective Study.Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure.Levosimendan restores the positive force-frequency relation in heart failure.Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failureEffects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failureA review of levosimendan in the treatment of heart failure.Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational studyLevosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.Levosimendan for the treatment of acute heart failure syndromes.Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass.Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery.Renal effects of levosimendan: a consensus report.Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.Effects of levo- and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli.[Heart in sepsis : Molecular mechanisms, diagnosis and therapy of septic cardiomyopathy].Levosimendan improves exercise performance in patients with advanced chronic heart failure.Intermittent levosimendan treatment in patients with severe congestive heart failure.Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats.[Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: Single-centered randomized prospective study.
P2860
Q24201225-7EFB0DFC-B98A-4711-AFE4-EB11E9D70EB0Q28212913-CF63AF5B-CFAB-4CC5-A86E-8B4BD82158DAQ33613185-55A2D7B6-9A2E-40CD-A16C-9C9DC8EC5049Q34498176-4F2629F2-1478-4120-9139-986CC6BD9261Q35159849-279F73F7-1602-480D-830F-A1DB4126FD79Q35384765-17E78B6C-3327-4A9D-8E6E-CD7A79DDCD03Q35772807-57F77523-9FF5-487C-BDAC-463983172D9BQ36013080-45176A29-6DA8-46F6-A96D-A885D8D31A24Q36070389-7EFBEEBB-375E-4AC4-9B51-A26EF74A6AE0Q36284075-C273AAAE-6344-43CB-9797-FFF4F0D59F04Q36326272-CEE92F34-3EC4-4463-8AE5-83CC39971444Q36772314-9FB14414-AD3B-4709-AD11-5128FDB4042BQ37019674-E4E104B7-6B30-4410-B95E-99354DE3CCABQ37314324-A42A7DC9-132F-4321-9ADB-7ED4EDAB6EEEQ37607413-DD476A71-9FF4-43FD-99AB-1729F71BBEB9Q38173852-04D9BC3F-2CC5-416E-BF9C-52D7AD5D1A2CQ39918710-997827D6-1109-4F82-98E6-23F2D499E194Q40147443-0ED19AFF-FE2E-4C5D-B204-3E8858451F97Q41226308-3D6809B1-6584-4185-B7D7-97C9BC3D5B0DQ43961914-288CFFBF-900D-4426-B208-9DE5553D0C25Q46952187-226F3E19-564C-4DB2-887A-DD975F370B4EQ47945310-3E0B4C05-EE35-4567-A6C2-67779531C5CFQ50457479-779D2B3E-BC09-419D-8399-8BD3643C35CEQ55263040-D47ADEBA-BA23-42F9-9F2A-19EC2C0227F3
P2860
The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The Ca2+-sensitizer levosimend ...... e in comparison to dobutamine.
@en
The Ca2+-sensitizer levosimend ...... e in comparison to dobutamine.
@nl
type
label
The Ca2+-sensitizer levosimend ...... e in comparison to dobutamine.
@en
The Ca2+-sensitizer levosimend ...... e in comparison to dobutamine.
@nl
prefLabel
The Ca2+-sensitizer levosimend ...... e in comparison to dobutamine.
@en
The Ca2+-sensitizer levosimend ...... e in comparison to dobutamine.
@nl
P2093
P2860
P1476
The Ca2+-sensitizer levosimend ...... e in comparison to dobutamine.
@en
P2093
Aris Androulakis
Catherine Avgeropoulou
Ioanna Andreadou
Ioannis Kallikazaros
Maritina Demopoulou
Platon Missovoulos
Sophia Markantonis-Kyroudis
P2860
P304
P356
10.1016/J.EJHEART.2005.02.002
P577
2005-08-01T00:00:00Z